Arlene Naranjo - Concepedia

Author

Arlene Naranjo

University of Florida ORCID

Also Known As

A Naranjo, A. Naranjo, Arlene H. Naranjo, Arlene Naranjo, Carrier, Kathryn S., Naranjo, A., À. Naranjo

253

Publications

6.9K

Citations

H-Index

Concepts

All Affiliations

University of Florida Children's Oncology Group Children's Hospital of Philadelphia Seattle Children's Hospital University of Washington

About

Arlene Naranjo is an author at University of Florida specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	31	2.2K
2	Health Sciences	8	8	368
3	Cell Biology	5	5	678
4	Cellular Therapies	2	2	94
5	Public Health	1	1	22

Arlene Naranjo

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations Thomas F. Eleveld, Derek A. Oldridge, Virginie Bernard, Nature Genetics Receptor Tyrosine KinasePathologyNeuroblastsTumor SuppressorCancer Genetics	2015	543
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group Meredith S. Irwin, Arlene Naranjo, Fan F. Zhang, Journal of Clinical Oncology	2021	439
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma Julie R. Park, Susan G. Kreissman, Wendy B. London, JAMA	2019	336
Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial Rajen Mody, Arlene Naranjo, Collin Van Ryn, The Lancet Oncology Cog Anbl1221Neuro-oncologyGliomaMedicineNeurology	2017	268
Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group Gregory A. Yanik, Marguerite T. Parisi, Barry L. Shulkin, Journal of Nuclear Medicine	2013	203
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak, Clinical Cancer Research	2021	200
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study Joëlle Vermeulen, Katleen De Preter, Arlene Naranjo, The Lancet Oncology Neuro-oncologyPediatric Brain TumorsPediatric NeurosurgeryRetrospective Siopen/cog/gpoh StudyPediatrics	2009	194
A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants Jed G. Nuchtern, Wendy B. London, Carol E. Barnewolt, Annals of Surgery	2012	193
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group Rajen Mody, Alice L. Yu, Arlene Naranjo, Journal of Clinical Oncology	2020	181
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations Samuel W. Brady, Yanling Liu, Xiaotu Ma, Nature Communications	2020	166

Page 1